Welcome to HitGen

Advancing Innovative Drug Discovery

Read more

Drug discovery,
it's in our DNA.

Read more

Enable Innovative
Drug Discovery with DEL,

Read more

Capabilities & Services

Enabling Innovative Drug Discovery with Advanced Technologies

  • DNA-encoded Library
  • Chemistry
  • Bioscience
  • Computational Sciences and Informatics
  • Structural Biology
  • Pre-clinical Studies
  • Clinical Development

Therapeutic Areas

Integrated One-stop Drug Discovery Platform   Accelerating Project with High Efficiency

  • Oncology and Immuno-oncology
  • Inflammatory and Autoimmune Diseases
  • Ophthalmology
  • Infectious Diseases
  • Metabolic Diseases
  • Cardiovascular Diseases
HitGen Inc. is a rapidly developing biotech company
The discovery and development of novel medicines and agrochemicals
>1 Trillion

DNA encoded compounds


novel drug/target complex structures for FBDD/SBDD

About Us

HitGen Inc. is a rapidly developing biotech company headquartered in Chengdu, China, with subsidiaries in Cambridge, UK and Houston, USA. It became a publicly listed company in Shanghai Stock Exchange in April 2020 (ticker code 688222.SH).  HitGen has established a drug discovery research platform for small molecules and nucleic acid drugs centered on the design, synthesis and screening of DNA encoded chemical libraries (DELs), fragment-based drug discovery (FBDD) and structure-based drug design (SBDD) technologies. HitGen's DELs currently contains more than 1 trillion novel, diverse, drug-like small molecules and macrocyclic compounds. These compounds are members of DELs synthesized from many hundreds of distinct chemical scaffolds, designed with tractable chemistry, and have yielded proven results for the discovery of small molecule leads against both precedented and unprecedented classes of biological targets.

Through its acquisition of Cambridge UK based Vernalis R&D Ltd, a leader in FBDD/SBDD, HitGen now has a research team of over 500 scientists and offers a full set of research capabilities from recombinant protein expression and purification, structural biology, assay development, screening, DEL synthesis, nucleic acid and small molecule chemical synthesis, computational and medicinal chemistry, biochemistry and biophysics, cell biology, in vivo pharmacology, DMPK, CMC, etc., to enable drug discovery research from target gene to IND filing.

HitGen operates a flexible business model, ranging from a single capability-based fee for services (FFS,e.g., protein expression and purification, structural biology, bioinformatics, computational chemistry, medicinal chemistry, nucleic and organic chemistry, analytical chemistry, biophysics, PK, PD, etc.), DEL screening, DEL design, synthesis and characterization, integrated drug discovery projects, risk sharing projects, collaborative ventures to program out-licensing. HitGen has approximately 20 in-house drug discovery programs at different stages of research & development. HitGen is collaborating with pharmaceutical, biotech and chemical companies, foundations and research institutes in North America, Europe, Asia, Africa and Australia to enable the discovery and development of novel medicines and agrochemicals.

Read More

Collaboration Partner

Latest News

  • 06 April 2021

    HitGen and BioAge Announce Research Progress in DNA-Encoded Library Based Drug Discovery Research Collaboration

    On 6th April 2021, CHENGDU, China-- Shanghai Stock Exchange listed biotech company HitGen Inc. (“HitGen”) announced important research progress in a collaboration with BioAge Labs, Inc. (“BioAge”), a private biotechnology company developing targeted small molecules for the treatment of diseases of aging. The companies have conducted collaborative research to identify and develop novel small-molecule compounds against a high-value and challenging biological target that is a critical component of the innate immune system. Dysregulation of this target is closely linked to the underlying cause of severe diseases in elderly humans, such as Alzheimer's and cardiovascular disease.
    + Read More
  • 10 March 2021

    Lipigon expands collaboration with HitGen by selecting second target

    Chengdu, China March 10th, 2021 Lipigon Pharmaceuticals AB (”Lipigon”), developer of therapeutics for lipid-related diseases, today announced that the company has expanded its agreement with the Shanghai STAR listed company HitGen Inc. (”HitGen”) to include a second novel target. With joint efforts, the aim is to develop a treatment for cardiometabolic disease.
    + Read More
  • 01 March 2021

    HitGen and UPPTHERA Enter Into Drug Discovery Research Collaboration

    CHENGDU, China, March 1st, 2021 -- HitGen (688222.SH) today announced that it has entered into a drug discovery research collaboration with UPPTHERA Inc. to identify small molecule Hits against previous known-to-be undruggable targets and novel E3 ligase. HitGen will apply its platform technology, based on the design, synthesis and screening of DNA-encoded libraries (DEL) to discover compounds that bind to certain targets. The identified compounds will be exclusively licensed to UPPTHERA for further development. Under the terms of the agreement, HitGen will receive an undisclosed upfront payment, success fee, license/milestone fee from UPPTHERA.
    + Read More

Latest Announcements,
Financial News and Stock Information

Read More


For more details on how we can advance your innovative drug discovery projects
By submitting your information, you acknowledge having received, read and understood our Privacy Notice as made available above.

We use cookies to provide a better web experience.
By using our site, you acknowledge our use of cookies and please read our Cookie Notice for More information